» Articles » PMID: 30115992

IL-17-dependent SIgA-mediated Protection Against Nasal Bordetella Pertussis Infection by Live Attenuated BPZE1 Vaccine

Overview
Journal Mucosal Immunol
Publisher Elsevier
Date 2018 Aug 18
PMID 30115992
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

BPZE1 is a live attenuated Bordetella pertussis vaccine for nasal administration to mimic the natural route of infection. Here, we studied the mechanism of BPZE1-induced immunity in the murine nasal cavity in contrast to acellular vaccine (aPV), although both vaccines protected against lung colonization. Transfer of splenocytes or serum from BPZE1-vaccinated or aPV-vaccinated mice protected naïve mice against lung colonization but not against nasal colonization. However, transfer of nasal washes from BPZE1-vaccinated mice resulted in protection against nasal colonization, which was lost in IgA-deficient or poly-Ig receptor-deficient mice, indicating that it depends on secretory IgA (SIgA) induction induced in the nose. BPZE1-induced protection against nasal colonization was long-lived despite the relatively rapid decay of SIgA, indicating a potent BPZE1-induced local memory response, likely due to CD4 tissue-resident memory T cells induced in the nose by BPZE1. These cells produced interleukin-17 (IL-17), known to be important for SIgA secretion. Furthermore, BPZE1 failed to protect Il17 mice against nasal colonization by B. pertussis and induced only background levels of nasal SIgA. Thus, our results show important differences in the protective mechanism between the upper and the lower murine respiratory tract and demonstrate an IL-17-dependent SIgA-mediated mechanism of BPZE1-induced protection against B. pertussis nasopharyngeal colonization.

Citing Articles

Pertussis before, during and after Covid-19.

Locht C EMBO Mol Med. 2025; .

PMID: 39994481 DOI: 10.1038/s44321-025-00199-2.


Mucosal vaccination with outer membrane vesicles derived from reduces nasal bacterial colonization after experimental infection.

Rudi E, Gaillard E, Bottero D, Ebensen T, Guzman C, Hozbor D Front Immunol. 2024; 15:1506638.

PMID: 39669568 PMC: 11635837. DOI: 10.3389/fimmu.2024.1506638.


A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge.

Kapil P, Wang Y, Gregg K, Zimmerman L, Molano D, Maldonado Villeda J mSphere. 2024; 9(11):e0064724.

PMID: 39441011 PMC: 11580402. DOI: 10.1128/msphere.00647-24.


A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis.

Galeas-Pena M, Hirsch A, Kuang E, Hoffmann J, Gellings P, Brown J NPJ Vaccines. 2024; 9(1):190.

PMID: 39406780 PMC: 11480359. DOI: 10.1038/s41541-024-00990-1.


Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions.

Kim A, Sette A, Da Silva Antunes R Expert Rev Vaccines. 2024; 23(1):705-714.

PMID: 39037200 PMC: 11306532. DOI: 10.1080/14760584.2024.2383745.